Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

Date Documents

Recent SEC Filings

Filing date Form Description Filing Group Downloads
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Other
0001959173-23-001625.rtf
0001959173-23-001625.pdf
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Other
0001959173-23-001524.rtf
0001959173-23-001524.pdf
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Other
0001959173-23-001529.rtf
0001959173-23-001529.xls
0001959173-23-001529.pdf
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Other
0001959173-23-001540.rtf
0001959173-23-001540.pdf
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Other
0001959173-23-001551.rtf
0001959173-23-001551.pdf
4

Statement of changes in beneficial ownership of securities
3,4,5
0001209191-23-033985.rtf
0001209191-23-033985.xls
0001209191-23-033985.pdf
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Other
0001959173-23-001412.rtf
0001959173-23-001412.pdf
4

Statement of changes in beneficial ownership of securities
3,4,5
0001209191-23-030141.rtf
0001209191-23-030141.xls
0001209191-23-030141.pdf
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Other
0001959173-23-001048.rtf
0001959173-23-001048.pdf
4

Statement of changes in beneficial ownership of securities
3,4,5
0001209191-23-029616.rtf
0001209191-23-029616.xls
0001209191-23-029616.pdf

Fact Sheets

There are currently no items available.

Recent Press Releases

Date Title and Summary
Toggle Summary Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira’s Amended and Restated
Toggle Summary Pacira Awarded New U.S. Patent Covering EXPAREL Composition
-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today
Toggle Summary Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new data
Toggle Summary Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 19 th at 3:00PM GMT (10:00AM
Toggle Summary Pacira BioSciences Reports Third Quarter 2024 Financial Results
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024.
Toggle Summary Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
-- Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act -- -- Beginning January 1, 2025, providers can receive additional Medicare payment when they use EXPAREL or iovera ° via product-specific reimbursement codes -- PARSIPPANY, N.J., Nov.
Toggle Summary Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call
Toggle Summary Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today
Toggle Summary Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’s Amended and Restated 2014
Toggle Summary Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain